Comparison of Sex Specific Data among Hospitalized Covid-19 Patients by Fleischer, BA, J. et al.
Bethlehe
m
Allentow
n
Monroe
Anderso
n
Quakertow
n
Miners
Warren
Introduction Results
Comparison of Sex Specific Data among Hospitalized Covid-19 Patients
Jessica G. Fleischer BA. 1 Rachel A. Pallay. 1 Douglas S. Corwin MD. 2
1. Lewis Katz School of Medicine at Temple University, Bethlehem, PA.  2. St. Luke’s Pulmonology/Critical Care, Bethlehem, PA. 
Methodology Analysis of Results References 
Risk factors stratified by biological sex showed that 
female patients were more likely to have COPD 
(p < 0.05) and asthma (p < 0.001), and less likely to 
have smoke exposure (p < 0.05). There was no 
statistically significant difference in any other 
predisposing risk factor - BMI, diabetes, 
hypertension, heart failure, coronary artery disease, 
COPD, immunosuppression, malignancy, chronic 
kidney disease - between sexes. There was no 
statistically significant difference in disease severity 
between the sexes with respect to intubation rate 
(p = 0.07) and mortality (p = 0.59). 
Discussion
The results of this study are important to show that the 
trend of increased severity among males may not be 
ubiquitous and care should be taken when considering 
male sex as an independent risk factor for disease 
severity. There are many limitations to this study. This 
is a preliminary study done with a small sample size of 
the first 689 COVID patients in the network, when 
ongoing treatment protocol modifications were being 
made with room for provider treatment bias and poor 
understanding of disease process. There is also an 
overrepresentation of obesity within the sample, which 
is a known risk factor for disease severity. Smoking 
status was evaluated via self report which is unreliabl  
and may introduce bias. Standardized reporting of 
pack-years would be a better way to evaluate and 
compare smoke exposure across disease severity. The 
methods used to determine disease severity 
(intubation, mortality) are a proxy for disease severity 
and do not represent all forms of severe disease. In 
future studies, factors such as admission to ICU, use of 
pressors, need for administration of Actemra, 
Ramdesivir, Convalescent Plasma, and anticoagulation 
will allow for a more complete investigation of disease 
severity. Other contributing factors to disease severity 
include race and ethnicity, neither of which were 
evaluated in this study. Finally, insurance and health 
systems in the US are different than in the rest of the 
world. Patients in this study population are either 
uninsured and likely waited until disease was very 
severe before seeking care, or have private insurance 
and were seeking care early in disease progression, 
whereas in countries with universal healthcare, patients 
could seek care at any point in disease progression. 
this may contribute to disparities when comparing this 
data to international data.
It is critical to identify factors that contribute to disease 
severity among patients diagnosed with COVID-19 to 
properly identify and treat infected patients. A 
systematic review of sex specific COVID-19 clinical 
outcomes demonstrated that female patients have 
lower rates of severe infection and mortality, raising the 
question of whether male sex is an independant risk 
factor for disease severity. Despite no difference in 
disease prevalence between sexes, men have 
consistently had higher rates of severe infection and 
mortality, with male mortality rates ranging from 2-4 
times the rates of female mortality. Interestingly, this 
data is consistent with the SARS outbreak. There have 
been several proposals as to why this is the case 
ranging from differences in biological factors, 
behavioral factors, and rates of comorbidities. First, the 
X chromosome is known to contain many immune 
genes, giving females a potential disease fighting 
advantage. Also, men are thought to have more ACE2 
receptors, the receptor the virus binds to gain entry into 
cells. Behaviorally, men are more likely to engage in 
risky behaviors and are more likely to smoke, which is a 
known risk factor for many comorbidities. 
This study investigates the correlation between biological 
sex and predisposing conditions as well as COVID-19 
disease severity among 689 patients hospitalized within 
the St. Luke’s Hospital Network in Eastern PA/Western 
NJ to identify if the trend of decreased severity in 
females holds true.
Aim of Study
Participants were 689 COVID-19 positive patients hospitalized within the St. Luke’s University Hospital
network. Data was extracted from patients electronic medical records both during their admission and
after discharge. Mean age of participants is 64.0 years (+/- 16.7). Male patients comprised 54.1% of the
sample while 45.9% were female. 57.9% of patients identified as Caucasian, 17.3% as African-American,
2.2% as Asian, less than 1% as Native-American, and 19.2% reported their race as “Other”. The sample
consisted of 30.2% of patients who reported their ethnicity as Hispanic or Latino, 66.0% who reported as
Not Hispanic or Latino, and the remaining 3.8% were unknown or other. The average BMI of participants
was 31.6 (+/- 7.8), where 54.1% of patients had a BMI of 30.0 or higher, 26.3% had a BMI between 25-
29.9, 18.6% of patients had a BMI between 18.6-24.9, and 1.0% of patients had a BMI <18.5. 62.7% of
patients never smoked tobacco, whereas 32.7% report quitting tobacco use and 4.2% are active tobacco
users. Chi squared test of independence was performed to examine the relation between known COVID-
19 risk factors and COVID-19 infected female patients (n=316) compared to male patients (n=373).
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Table 2. Demographic Data
Patient Sex
Female Male Total
Age Over 50 81.0% 77.2% 79.0%
49 and Under 19.0% 22.8% 21.0%
Race American Indian or Alaska Native 0.3% 0.3% 0.3%
Asian or Asian American 2.2% 2.1% 2.2%
Black or African American 16.5% 18.0% 17.3%
White or Caucasian 63.3% 53.6% 58.1%
Other Race 14.9% 22.8% 19.2%
Unknown/Declined 2.8% 3.2% 3.0%
Ethnicity Hispanic or Latino 25.3% 34.3% 30.2%
Not Hispanic or Latino or Spanish 71.2% 61.7% 66.0%
Not Reported/Declined to Answer 1.9% 1.9% 1.9%
Other/Unknown 1.6% 2.1% 1.9%
BMI Underweight 1.9% 0.3% 1.0%
Normal 19.6% 17.7% 18.6%
Overweight 22.2% 29.8% 26.3%
Obese 56.3% 52.3% 54.1%
Tobacco Use Never 67.7% 58.4% 62.7%
Quit 28.5% 36.2% 32.7%
Current 3.2% 5.1% 4.2%
Unknown 0.6% 0.3% 0.4%
Table 1. Risk Factors & Chi Square Analysis
Patient Sex
Risk Factor Female Male Total P Value
% % %
BMI Normal 21.5% 18.0% 19.6% 0.241
Overweight/Obese 78.5% 82.0% 80.4%
Smoking Exposure Exposure 32.3% 41.6% 37.3% 0.012
Never 67.7% 58.4% 62.7%
Diabetes No 60.8% 56.3% 58.3% 0.445
Yes 39.2% 43.7% 41.7%
HTN No 40.2% 42.1% 41.2% 0.613
Yes 59.8% 57.9% 58.8%
HF No 86.1% 86.6% 86.4% 0.843
Yes 13.9% 13.4% 13.6%
CAD No 85.4% 82.6% 83.9% 0.307
Yes 14.6% 17.4% 16.1%
COPD No 88.6% 93.0% 91.0% 0.043
Yes 11.4% 7.0% 9.0%
Asthma No 82.3% 91.7% 87.4% <0.001
Yes 17.7% 8.3% 12.6%
Immunosuppression No 94.3% 94.4% 94.3% 0.970
Yes 5.7% 5.6% 5.7%
Malignancy No 91.1% 89.5% 90.3% 0.481
Yes 8.9% 10.5% 9.7%
CKD No 81.0% 79.9% 80.4% 0.712
Yes 19.0% 20.1% 19.6%
Intubation No 88.3% 83.4% 85.6% 0.067
Yes 11.7% 16.6% 14.4%
Mortality Expired 16.8% 15.3% 16.0% 0.595
Survived 83.2% 84.7% 84.0%
